#United States #Charleston, S.C. #Twirla®; Afaxys; Exeltis

Renewed Partnership: Afaxys and Exeltis

Afaxys, Inc., a unique Public Benefit Corporation focusing on socially responsible healthcare solutions, has announced a renewal of its partnership with Exeltis USA. This strategic alliance aims to enhance access to the Twirla® transdermal system—an innovative contraceptive method designed to empower women by providing convenient birth control options. This initiative is a significant leap forward in their commitment to improving reproductive health outcomes across the United States.

The renewal comes on the heels of Exeltis’ acquisition of Agile Therapeutics in August 2024, further emphasizing the importance of collaboration in advancing public health initiatives. Historically, Afaxys has prioritized ensuring public health professionals have the necessary tools and support to deliver effective care to patients. Ronda Dean, CEO and Co-Founder of Afaxys, stated, “Our partnership with Exeltis reflects our shared vision to ensure that women have consistent access to high-quality, affordable contraceptive options that fit their lifestyles.”

What is Twirla®?

Twirla (levonorgestrel and ethinyl estradiol), the combined hormonal contraceptive, is a transdermal patch applied once a week, for three weeks, followed by a patch-free week. Unlike traditional daily contraceptive pills, Twirla offers a non-daily method for women, designed with their busy lifestyles in mind, while providing effective contraception with a lower dose of hormones. The patch is specifically recommended for women with a body mass index (BMI) under 30 kg/m², and healthcare providers are urged to consider individual BMI before prescribing.

Importance of Expanded Access

The renewed partnership between Afaxys and Exeltis demonstrates a collaborative approach to public health. By leveraging their combined resources, both organizations aim to create greater availability of Twirla and other innovative contraceptive products in the U.S. public health market. Eduardo Fernandez, EVP of Corporate Development at Exeltis USA, added, “Together with Afaxys, we're making it easier for women to access Twirla—when and where they need it.” This commitment ensures that women across the country will continue to receive well-researched products that align with their personal health needs.

Supporting Healthcare Professionals

The alliance is not merely about providing drugs; it's also about education and support. Afaxys and Exeltis will continue to equip healthcare professionals with vital resources and training necessary to improve the reproductive health landscape in America. This initiative highlights the critical role of healthcare providers in navigating reproductive health options, demonstrating a commitment to furthering access and understanding of contraceptive methods.

Christian Bloomgren, President and CCO of Afaxys, expressed that this partnership furthers their mission to broaden healthcare solutions available to public professionals and their patients. The collaboration will drive innovative products that address the varying needs of women across different demographics, ensuring that every woman has access to the contraceptive method that best suits her.

About Afaxys and Exeltis

Afaxys operates through several subsidiaries, offering various reproductive health products including both generic and branded contraceptives. Established with the intent to streamline access to reproductive health options, Afaxys works closely with healthcare professionals to provide stable pricing and dependable services necessary for patient care.

Exeltis, part of the Insud Pharma group, is a global leader dedicated to advancing women's health, providing innovative solutions and high-quality prescription products specifically designed to meet evolving patient needs. Insud Pharma, with a rich history spanning over 45 years and a presence in around 50 nations, focuses on improving global health through effective, safe, and accessible treatments.

Conclusion

The renewal of this partnership between Afaxys and Exeltis signifies a powerful collaboration aimed at providing women with unprecedented access to effective contraception like Twirla. The proactive steps that both companies are implementing reflect a profound recognition of the complexities involved in women’s health and the imperative to ensure that innovative solutions are available to those who need them. Through this partnership, Afaxys and Exeltis are not only enhancing reproductive health services but also paving the way for a healthier future where women can access essential healthcare without barriers.